GutMind develops targeted probiotic formulations that enhance gut health by utilizing familiar foods from the Western diet. The company addresses health issues linked to poor dietary habits without requiring significant changes to consumers' eating patterns.
Funding
Funding not disclosed
Founders
Product
Problem
The Western Pattern Diet (WPD) contributes to various health issues due to its excess of unhealthy compounds and lack of essential nutrients. Traditional approaches to improving health often require significant and difficult-to-achieve changes in dietary habits. Many individuals do not obtain sufficient key functional nutrients, which are critical for both mental and physical well-being, through their regular food intake or supplements.
Solution
GutMind is developing recombinant probiotic solutions designed to address health problems associated with the Western Pattern Diet (WPD). Their Bacterissima™ platform utilizes engineered probiotics to convert excess sugars present in the WPD into key functional nutrients, such as omega-3 fatty acids, directly within the digestive tract. This in-situ conversion aims to overcome limitations of traditional supplements, such as bioavailability issues, by providing beneficial nutrients for immediate uptake. By incorporating these probiotics into familiar foods, GutMind seeks to improve health outcomes without requiring drastic changes to consumers' existing dietary habits. The company intends to commercialize its proprietary probiotics through licensing agreements with supplement and food companies, as well as through its own branded products.
Target Audience
The primary target audience includes consumers adhering to a Western Pattern Diet, supplement and food companies seeking innovative ingredients, and individuals looking to improve their nutrient intake without significant dietary changes.
Features
- Recombinant probiotic platform for in-situ conversion of excess sugar into functional nutrients.
- Production of key nutrients like omega-3 fatty acids within the digestive tract for improved bioavailability.
- Engineered probiotic strains developed using precision gene editing technology.
- Metabolic pathway design and integration into probiotic genomes using in-silico methods.
- Iterative strain testing under in vitro and in vivo conditions for functional nutrient production.
- Application of machine learning AI across transcriptomic, postbiotic, and microbiome data sets.
- Probiotic manufacturing leveraging established microbial fermentation and encapsulation technologies.